About 333 results

ALLMedicine™ Hyperglucagonemia Center

Research & Reviews  111 results

Implication of sugar, protein and incretins in excessive glucagon secretion in type 2 d...
Clinical Nutrition (Edinburgh, Scotland); Zhang J, Schäfer SM et. al.

Mar 2nd, 2023 - Amino acids powerfully release glucagon but their contribution to postprandial hyperglucagonemia in type 2 diabetes remains unclear. Exogenously applied GIP stimulates, while GLP-1 inhibits, glucagon secretion in humans. However, their role in mix...

Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucag...
Metabolism: Clinical and Experimental; Chen X, Merovci A et. al.

Feb 7th, 2023 - Hyperglucagonemia is a characteristic feature of type 2 diabetes mellitus (T2DM). We examined the effect of chronic (48-72 h) physiologic increase (+50 mg/dl) in plasma glucose concentration on suppression of plasma glucagon concentration by insul...

Glucagon in type 2 diabetes: Friend or foe?
Diabetes/metabolism Research and Reviews; Caruso I, Marrano N et. al.

Jan 14th, 2023 - Hyperglucagonemia is one of the 'ominous' eight factors underlying the pathogenesis of type 2 diabetes (T2D). Glucagon is a peptide hormone involved in maintaining glucose homoeostasis by increasing hepatic glucose output to counterbalance insulin...

GC-Globulin/Vitamin D-Binding Protein Is Required for Pancreatic α-Cell Adaptation to M...
Diabetes Viloria K, Nasteska D et. al.

Nov 30th, 2022 - GC-globulin (GC), or vitamin D-binding protein, is a multifunctional protein involved in the transport of circulating vitamin 25(OH)D and fatty acids, as well as actin scavenging. In the pancreatic islets, the gene encoding GC, GC/Gc, is highly lo...

G protein-coupled lactate receptor GPR81 control of ventrolateral ventromedial hypothal...
American Journal of Physiology. Regulatory, Integrative A... Roy SC, Napit PR et. al.

Nov 22nd, 2022 - Astrocytes store glycogen as energy and promote neurometabolic stability through supply of oxidizable l-lactate. Whether lactate regulates ventromedial hypothalamic nucleus (VMN) glucostatic function as a metabolic volume transmitter is unknown. C...

see more →

Clinicaltrials.gov  18 results

Glucagon Resistance in Patients With NAFLD

Nov 4th, 2022 - The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Moreover, they propose a dys-coordinated, reduced glucagon se...

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes

Oct 7th, 2022 - Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9 years, the absence ...

Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis

May 18th, 2022 - Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (long-term) and non- transcriptional (acute) mecha...

Lowering Impaired Fasting Glucose Levels With Exercise

Oct 21st, 2021 - In individuals with type 2 diabetes (T2D), chronically elevated glucose and insulin levels result in numerous health complications. Maintaining tight glucose control is difficult for individuals with T2D, particularly in the postprandial period an...

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover

Apr 30th, 2021 - Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia. This contributes to the hyperglycaemic state of the patients and is considered an important c...

see more →

News  4 results

Multiple Metabolic Abnormalities Seen in Lupus

Apr 4th, 2017 - Lupus patients had a bi-hormone metabolic abnormality characterized by increased insulin resistance and glucagon levels, despite normal glucose tolerance, according to a Brazilian study. When compared with a control group, patients with systemic l...

Glucagon Receptor Blockers Eyed for Type 2
Miriam E. Tucker

Oct 1st, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.

Investigational Glucagon Antagonists Show Promise for Diabetes
Miriam E. Tucker

Sep 16th, 2011 - LISBON – New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes, but only if safety can be established, according to two presentations at.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

Abstract and Introduction Abstract Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in ...

see more →